Septa Pharmaceuticals Strengthens Its Oncology Portfolio with CeeNU Acquisition
Septa Pharmaceuticals Expands Oncology Portfolio with CeeNU Acquisition
Mississauga, Ontario – July 15, 2026 – In a significant move to bolster its presence in the oncology sector, Septa Pharmaceuticals Inc. is thrilled to announce the successful acquisition of CeeNU® (lomustine) from Bristol Myers Squibb Canada. This strategic acquisition became effective on June 29, 2026, marking a pivotal moment in Septa's commitment to enhancing its specialized pharmaceutical product offerings.
CeeNU® (lomustine) is a well-established alkylating agent widely used in the treatment of specific brain tumors and Hodgkin’s lymphoma. By integrating this essential chemotherapy drug into its product lineup, Septa reinforces its position in both oncology and critical care. This acquisition not only enhances the company’s portfolio but also signifies its resolve to provide robust options for healthcare professionals and patients facing severe health challenges.
Septa Pharmaceuticals recognizes the critical need for uninterrupted access to life-saving medications.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.